ASCO will grade drugs

Share this article:

The American Society of Clinical Oncology is taking notes. BioCentury reports that the professional society is grading cancer drugs based on benefit, toxicity and cost.

Chief Medical Officer Richard Schilsky told BioCentury that the scorecard is necessary because the price of a drug does not always reflect its impact.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions